Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy

Wenxiao YANG; Linwei GUO; Hong LING; Xin HU

doi:10.19401/j.cnki.1007-3639.2023.05.009

您当前的位置：

首页 >

文章列表页 >

Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy

Article | 更新时间：2025-12-31

- Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
- China Oncology Vol. 33, Issue 5, Pages: 484-498(2023)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系，上海 200032
  2. 复旦大学附属肿瘤医院精准肿瘤中心，复旦大学上海医学院肿瘤学系，上海 200032
  3. 复旦大学附属肿瘤医院大肠外科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.05.009
  CLC： R737.9
- Received：31 January 2023，
  
  Revised：2023-04-26，
  
  Published：30 May 2023
- 稿件说明：
移动端阅览
Wenxiao YANG, Linwei GUO, Hong LING, et al. Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy[J]. China Oncology, 2023, 33(5): 484-498.
DOI：

Wenxiao YANG, Linwei GUO, Hong LING, et al. Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy[J]. China Oncology, 2023, 33(5): 484-498. DOI： 10.19401/j.cnki.1007-3639.2023.05.009.

摘要

背景与目的：

人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性乳腺癌患者的肿瘤免疫微环境（tumor immune microenvironment，TIME）与曲妥珠单抗治疗效果显著相关，提示免疫检查点疗法联合曲妥珠单抗治疗的临床潜力。本研究旨在探索HER2阳性乳腺癌联合治疗的预测因子，筛选联合治疗的潜在获益人群。

方法：

纳入高通量基因表达（Gene Expression Omnibus，GEO）数据库中509例接受曲妥珠单抗治疗的HER2阳性乳腺癌患者和癌症基因组图谱（The Cancer Genome Atlas，TCGA）数据库中67例HER2阳性乳腺癌患者的转录组与基因组数据，筛选曲妥珠单抗耐药组的差异表达基因进行功能富集分析、蛋白质互作网络构建。结合临床信息通过对数秩检验和多因素COX比例风险回归模型构建预测模型。并利用CIBERSORT反卷积法分析TIME特征，通过肿瘤免疫功能障碍和排斥（tumor immune dysfunction and exclusion，TIDE）评分预测免疫治疗获益。

结果：

通过分析曲妥珠单抗缓解组和曲妥珠单抗耐药组之间的免疫微环境与基因表达特征，构建了由4个核心基因（

GATA

6、

TRPV

6、

AMACR

、

ZHX

2）组成的曲妥珠单抗相关基因预测指数（trastuzumab related genetic prognostic index，TRGPI）。低TRGPI评分的患者的TIME含有更高比例的CD8

T淋巴细胞和激活的自然杀伤细胞，同时程序性死亡[蛋白

]

-1（programmed death-1，PD-1）的表达更高，更倾向于从曲妥珠单抗联合免疫治疗中获益。

结论：

本研究基于TIME重新定义了HER2阳性乳腺癌曲妥珠单抗联合免疫治疗的获益人群，并为临床应用提供了可选的治疗策略。

Abstract

Background and Purpose:

The tumor immune microenvironment (TIME) of breast cancer with positive human epidermal growth factor receptor 2 (HER2) is significantly related to the efficacy of trastuzumab

indicating the clinical potential of immunocheckpoint therapy combined with trastuzumab. This study aimed to explore the predictors of HER2-positive breast cancer combination therapy and screen the potential beneficiaries of combination therapy.

Methods:

Transcriptome and genome data of 509 HER2-positive breast cancer samples of patients receiving trastuzumab treatment from Gene Expression Omnibus (GEO) database and 67 HER2-posi

tive breast cancer samples from The Cancer Genome Atlas (TCGA) databases were collected. Trastuzumab-resistant group’s differentially expressed genes were identified and analyzed for functional enrichment and protein-protein interaction. The log-rank test and multivariate COX proportional hazards regression were used with clinical data to create the prediction model. The TIME landscape was characterized using the CIBERSORT. The immunotherapy benefit was valued by the tumor immune dysfunction and exclusion (TIDE) score.

Results:

The trastuzumab related genetic prognostic index (TRGPI) consisting of four hub genes (

GATA

TRPV

AMACR

ZHX

2) was constructed by analyzing the immune microenvironment and gene expression characteristics between trastuzumab-remission group and trastuzumab-resistance group. Importantly

the results revealed that patients with lower TRPGI were trastuzumab-sensitive and more likely to benefit from immunotherapy because of the increased percentages of CD8

T cells

active natural killer cells and programmed death-1 (PD-1) expression.

Conclusion:

This study redefined the benefit population through TIME and provided a selectable strategy of trastuzumab plus immunotherapy for HER2-positive breast cancer.

关键词

Keywords

references

SLAMON D J , CLARK G M , WONG S G , et al . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene [J ] . Science , 1987 , 235 ( 4785 ): 177 - 182 . DOI: 10.1126/science.3798106 http://doi.org/10.1126/science.3798106

SWAIN S M , SHASTRY M , HAMILTON E . Targeting HER2-positive breast cancer: advances and future directions [J ] . Nat Rev Drug Discov , 2023 , 22 ( 2 ): 101 - 126 . DOI: 10.1038/s41573-022-00579-0 http://doi.org/10.1038/s41573-022-00579-0

SLAMON D J , LEYLAND-JONES B , SHAK S , et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J ] . N Engl J Med , 2001 , 344 ( 11 ): 783 - 792 . DOI: 10.1056/NEJM200103153441101 http://doi.org/10.1056/NEJM200103153441101 http://www.nejm.org/doi/abs/10.1056/NEJM200103153441101 http://www.nejm.org/doi/abs/10.1056/NEJM200103153441101

VOGEL C L , COBLEIGH M A , TRIPATHY D , et al . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer [J ] . J Clin Oncol , 2002 , 20 ( 3 ): 719 - 726 . DOI: 10.1200/JCO.2002.20.3.719 http://doi.org/10.1200/JCO.2002.20.3.719

GENNARI R , MENARD S , FAGNONI F , et al . Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 [J ] . Clin Cancer Res , 2004 , 10 ( 17 ): 5650 - 5655 . DOI: 10.1158/1078-0432.CCR-04-0225 http://doi.org/10.1158/1078-0432.CCR-04-0225

BUSSOLATI G , MONTEMURRO F , RIGHI L , et al . A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer [J ] . Br J Cancer , 2005 , 92 ( 7 ): 1261 - 1267 . DOI: 10.1038/sj.bjc.6602507 http://doi.org/10.1038/sj.bjc.6602507

DIERMEIER S , HORVÁTH G , KNUECHEL-CLARKE R , et al . Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation [J ] . Exp Cell Res , 2005 , 304 ( 2 ): 604 - 619 . DOI: 10.1016/j.yexcr.2004.12.008 http://doi.org/10.1016/j.yexcr.2004.12.008

LU Y , ZI X , ZHAO Y , et al . Insulin-like growth factor-Ⅰ receptor signaling and resistance to trastuzumab (Herceptin) [J ] . J Natl Cancer Inst , 2001 , 93 ( 24 ): 1852 - 1857 . DOI: 10.1093/jnci/93.24.1852 http://doi.org/10.1093/jnci/93.24.1852 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/93.24.1852 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/93.24.1852

NAGATA Y , LAN K H , ZHOU X Y , et al . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients [J ] . Cancer Cell , 2004 , 6 ( 2 ): 117 - 127 . DOI: 10.1016/j.ccr.2004.06.022 http://doi.org/10.1016/j.ccr.2004.06.022

LOI S , GIOBBIE-HURDER A , GOMBOS A , et al . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial [J ] . Lancet Oncol , 2019 , 20 ( 3 ): 371 - 382 . DOI: S1470-2045(18)30812-X http://doi.org/S1470-2045(18)30812-X

STAGG J , LOI S , DIVISEKERA U , et al . Anti-ErbB-2 MAb therapy requires type Ⅰ and Ⅱ interferons and synergizes with anti-PD-1 or anti-CD137 MAb therapy [J ] . Proc Natl Acad Sci U S A , 2011 , 108 ( 17 ): 7142 - 7147 . DOI: 10.1073/pnas.1016569108 http://doi.org/10.1073/pnas.1016569108 https://pnas.org/doi/full/10.1073/pnas.1016569108 https://pnas.org/doi/full/10.1073/pnas.1016569108

BASELGA J , BRADBURY I , EIDTMANN H , et al . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet , 2012 , 379 ( 9816 ): 633 - 640 . DOI: 10.1016/S0140-6736(11)61847-3 http://doi.org/10.1016/S0140-6736(11)61847-3

CAREY L A , BERRY D A , CIRRINCIONE C T , et al . Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase Ⅲ trial of paclitaxel plus trastuzumab with or without lapatinib [J ] . J Clin Oncol , 2016 , 34 ( 6 ): 542 - 549 .

GIANNI L , PIENKOWSKI T , IM Y H , et al . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J ] . Lancet Oncol , 2012 , 13 ( 1 ): 25 - 32 . DOI: 10.1016/S1470-2045(11)70336-9 http://doi.org/10.1016/S1470-2045(11)70336-9

SCHNEEWEISS A , CHIA S , HICKISH T , et al . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2278 - 2284 . DOI: 10.1093/annonc/mdt182 http://doi.org/10.1093/annonc/mdt182 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297

GIORDANO S H , FRANZOI M A B , TEMIN S , et al . Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update [J ] . J Clin Oncol , 2022 , 40 ( 23 ): 2612 - 2635 .

FU Z W , LI S J , HAN S F , et al . Antibody drug conjugate: the “biological missile” for targeted cancer therapy [J ] . Signal Transduct Target Ther , 2022 , 7 ( 1 ): 93 .

TORRES E T R , EMENS L A . Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies [J ] . Breast Cancer Res Treat , 2022 , 191 ( 2 ): 291 - 302 . DOI: 10.1007/s10549-021-06423-0 http://doi.org/10.1007/s10549-021-06423-0

FERNANDEZ-MARTINEZ A , PASCUAL T , SINGH B , et al . Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials [J ] . JAMA Oncol , 2023 , 9 ( 4 ): 490 - 499 . DOI: 10.1001/jamaoncol.2022.6288 http://doi.org/10.1001/jamaoncol.2022.6288 https://jamanetwork.com/journals/jamaoncology/fullarticle/2800243 https://jamanetwork.com/journals/jamaoncology/fullarticle/2800243

SHARMA P , HU-LIESKOVAN S , WARGO J A , et al . Primary, adaptive, and acquired resistance to cancer immunotherapy [J ] . Cell , 2017 , 168 ( 4 ): 707 - 723 . DOI: S0092-8674(17)30065-X http://doi.org/S0092-8674(17)30065-X

KALAORA S , NAGLER A , WARGO J A , et al . Mechanisms of immune activation and regulation: lessons from melanoma [J ] . Nat Rev Cancer , 2022 , 22 ( 4 ): 195 - 207 . DOI: 10.1038/s41568-022-00442-9 http://doi.org/10.1038/s41568-022-00442-9

LABRIE M , BRUGGE J S , MILLS G B , et al . Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer [J ] . Nat Rev Cancer , 2022 , 22 ( 6 ): 323 - 339 . DOI: 10.1038/s41568-022-00454-5 http://doi.org/10.1038/s41568-022-00454-5

COOLEY S , BURNS L J , REPKA T , et al . Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu [J ] . Exp Hematol , 1999 , 27 ( 10 ): 1533 - 1541 . DOI: 10.1016/s0301-472x(99)00089-2 http://doi.org/10.1016/s0301-472x(99)00089-2

LEWIS G D , FIGARI I , FENDLY B , et al . Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies [J ] . Cancer Immunol Immunother , 1993 , 37 ( 4 ): 255 - 263 . DOI: 10.1007/BF01518520 http://doi.org/10.1007/BF01518520 http://link.springer.com/10.1007/BF01518520 http://link.springer.com/10.1007/BF01518520

KOHRT H E , HOUOT R , MARABELLE A , et al . Combination strategies to enhance antitumor ADCC [J ] . Immunotherapy , 2012 , 4 ( 5 ): 511 - 527 . DOI: 10.2217/imt.12.38 http://doi.org/10.2217/imt.12.38

CLYNES R A , TOWERS T L , PRESTA L G , et al . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets [J ] . Nat Med , 2000 , 6 ( 4 ): 443 - 446 . DOI: 10.1038/74704 http://doi.org/10.1038/74704

SALGADO R , DENKERT C , CAMPBELL C , et al . Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial [J ] . JAMA Oncol , 2015 , 1 ( 4 ): 448 - 454 . DOI: 10.1001/jamaoncol.2015.0830 http://doi.org/10.1001/jamaoncol.2015.0830

CORTAZAR P , ZHANG L J , UNTCH M , et al . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J ] . Lancet , 2014 , 384 ( 9938 ): 164 - 172 . DOI: 10.1016/S0140-6736(13)62422-8 http://doi.org/10.1016/S0140-6736(13)62422-8

INGOLD HEPPNER B , UNTCH M , DENKERT C , et al . Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer [J ] . Clin Cancer Res , 2016 , 22 ( 23 ): 5747 - 5754 .

CHIC N , LUEN S J , NUCIFORO P , et al . Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer [J ] . J Natl Cancer Inst , 2022 , 114 ( 3 ): 467 - 470 . DOI: 10.1093/jnci/djab057 http://doi.org/10.1093/jnci/djab057 https://academic.oup.com/jnci/article/114/3/467/6206389 https://academic.oup.com/jnci/article/114/3/467/6206389

DENKERT C , VON MINCKWITZ G , BRASE J C , et al . Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers [J ] . J Clin Oncol , 2015 , 33 ( 9 ): 983 - 991 . DOI: 10.1200/JCO.2014.58.1967 http://doi.org/10.1200/JCO.2014.58.1967

RITCHIE M E , PHIPSON B , WU D , et al . Limma powers differential expression analyses for RNA-sequencing and microarray studies [J ] . Nucleic Acids Res , 2015 , 43 ( 7 ): e47.

CHALMERS Z R , CONNELLY C F , FABRIZIO D , et al . Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden [J ] . Genome Med , 2017 , 9 ( 1 ): 34 . DOI: 10.1186/s13073-017-0424-2 http://doi.org/10.1186/s13073-017-0424-2

NEWMAN A M , LIU C L , GREEN M R , et al . Robust enumeration of cell subsets from tissue expression profiles [J ] . Nat Methods , 2015 , 12 ( 5 ): 453 - 457 . DOI: 10.1038/nmeth.3337 http://doi.org/10.1038/nmeth.3337

THORSSON V , GIBBS D L , BROWN S D , et al . The immune landscape of cancer [J ] . Immunity , 2018 , 48 ( 4 ): 812 - 830 .e14. DOI: S1074-7613(18)30121-3 http://doi.org/S1074-7613(18)30121-3

LAUSS M , DONIA M , HARBST K , et al . Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma [J ] . Nat Commun , 2017 , 8 ( 1 ): 1738 . DOI: 10.1038/s41467-017-01460-0 http://doi.org/10.1038/s41467-017-01460-0

JIANG P , GU S Q , PAN D , et al . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response [J ] . Nat Med , 2018 , 24 ( 10 ): 1550 - 1558 . DOI: 10.1038/s41591-018-0136-1 http://doi.org/10.1038/s41591-018-0136-1

SCHOENFELD A J , RIZVI H , BANDLAMUDI C , et al . Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas [J ] . Ann Oncol , 2020 , 31 ( 5 ): 599 - 608 . DOI: S0923-7534(20)36018-X http://doi.org/S0923-7534(20)36018-X

JENSEN J D , KNOOP A , LAENKHOLM A V , et al . PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab [J ] . Ann Oncol , 2012 , 23 ( 8 ): 2034 - 2042 . DOI: S0923-7534(19)38088-3 http://doi.org/S0923-7534(19)38088-3

VIGANO S , ALATZOGLOU D , IRVING M , et al . Targeting adenosine in cancer immunotherapy to enhance T-cell function [J ] . Front Immunol , 2019 , 10 : 925 . DOI: 10.3389/fimmu.2019.00925 http://doi.org/10.3389/fimmu.2019.00925

YAMAMOTO K , VENIDA A , YANO J , et al . Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I [J ] . Nature , 2020 , 581 ( 7806 ): 100 - 105 . DOI: 10.1038/s41586-020-2229-5 http://doi.org/10.1038/s41586-020-2229-5

PRAT A , GUARNERI V , PASCUAL T , et al . Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer [J ] . EBioMedicine , 2022 , 75 : 103801 . DOI: 10.1016/j.ebiom.2021.103801 http://doi.org/10.1016/j.ebiom.2021.103801 https://linkinghub.elsevier.com/retrieve/pii/S2352396421005958 https://linkinghub.elsevier.com/retrieve/pii/S2352396421005958

FERNANDEZ-MARTINEZ A , KROP I E , HILLMAN D W , et al . Survival, pathologic response, and genomics in CALGB 40601 (alliance), a neoadjuvant phase Ⅲ trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer [J ] . J Clin Oncol , 2020 , 38 ( 35 ): 4184 - 4193 . DOI: 10.1200/JCO.20.01276 http://doi.org/10.1200/JCO.20.01276 https://ascopubs.org/doi/10.1200/JCO.20.01276 https://ascopubs.org/doi/10.1200/JCO.20.01276

WONG H , LEUNG R , KWONG A , et al . Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer [J ] . Oncologist , 2011 , 16 ( 11 ): 1535 - 1546 . DOI: 10.1634/theoncologist.2011-0165 http://doi.org/10.1634/theoncologist.2011-0165 https://academic.oup.com/oncolo/article/16/11/1535/6400831 https://academic.oup.com/oncolo/article/16/11/1535/6400831

MITTAL D , CARAMIA F , MICHIELS S , et al . Improved treatment of breast cancer with anti-HER2 therapy requires interleukin-21 signaling in CD8+ T cells [J ] . Cancer Res , 2016 , 76 ( 2 ): 264 - 274 . DOI: 10.1158/0008-5472.CAN-15-1567 http://doi.org/10.1158/0008-5472.CAN-15-1567

KILLOCK D . Targeted therapy: leveraging ADCC to enhance anti-HER2 therapy [J ] . Nat Rev Clin Oncol , 2017 , 14 ( 4 ): 200 . DOI: 10.1038/nrclinonc.2017.19 http://doi.org/10.1038/nrclinonc.2017.19

ROSENBERG S A , YANG J C , SHERRY R M , et al . Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy [J ] . Clin Cancer Res , 2011 , 17 ( 13 ): 4550 - 4557 . DOI: 10.1158/1078-0432.CCR-11-0116 http://doi.org/10.1158/1078-0432.CCR-11-0116

VESELY M D , KERSHAW M H , SCHREIBER R D , et al . Natural innate and adaptive immunity to cancer [J ] . Annu Rev Immunol , 2011 , 29 : 235 - 271 . DOI: 10.1146/annurev-immunol-031210-101324 http://doi.org/10.1146/annurev-immunol-031210-101324

Views

1656

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in models predicting efficacy of immune checkpoint inhibitors

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

A study on the immunomicroenvironment characteristics of gastric cancer with neuroendocrine neoplasm and pure gastric cancer

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Related Author

Yingyao CHEN

Xiangling CHU

Xin YU

Chunxia SU

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

Related Institution

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰